PharmAla To Supply Ostfold Hospital Trust with LaNeo(TM) MDMA for Clinical Research

Executive Summary

• PharmAla Biotech Holdings Inc. has executed a sales agreement to supply LaNeo™ MDMA clinical research material to Østfold Hospital Trust in Norway.
• The agreement includes financial terms, data‑sharing provisions, and will commence once regulatory approvals are obtained.
• Discounts may be offered in exchange for data sharing; the partnership aims to support clinical research into MDMA for Major Depressive Disorder.

Key Details

• Parties: PharmAla Biotech Holdings Inc. (CSE: MDMA / OTCQB: MDXXF) and Østfold Hospital Trust (Norway).
• Product: LaNeo™ MDMA Clinical Research Materials (MDXX class molecules).
• Agreement Scope: Supply of investigational MDMA for clinical research, subject to customary regulatory approvals.
• Financial Terms: Not disclosed; includes standard financial provisions and potential discounts tied to data‑sharing arrangements.
• Data‑Sharing Provisions: PharmAla will consider discount incentives where appropriate in exchange for access to research data generated by Østfold Hospital Trust.
• Regulatory Conditions: Shipment to commence at the earliest opportunity after obtaining required regulatory clearances.
• Operational Support: Researchers can access drug product quality information via https://pharmala.ca/clinical‑trials.
• Contact for Qualified Researchers: [email protected].

Notable Quotes

“It was gratifying to be selected as the supplier to Østfold Hospital Trust… We are excited and committed to help support them in their goal, and look forward to delivering investigational LaNeo MDMA to them…” – Nicholas Kadysh, CEO, PharmAla Biotech.

“PharmAla was selected after a competitive review of potential manufacturers… Their demonstrated professionalism… made them a strong partner for this study.” – Tor‑Morten Kvam, Østfold Hospital Trust.